ELV monthly performance report
Check ELV's monthly returns, drawdown, and seasonality trends — updated every month.
ELV monthly report
—
Key takeaways
- Elevance Health (ELV) closed November 2026 at $429.90, up 2.34% for the month and +31.22% over the trailing 12 months.
- Year-to-date, ELV is +22.64%, outperforming the S&P 500 which has returned +11.03% YTD.
- The stock is trading +14.83% versus its 200-day moving average ($374.39), a bullish technical signal.
- Over the past three years, ELV has underperformed the S&P 500 by −78.02%, with a relative strength index reading of 54.2.
- Win rate over the trailing 39 months stands at 59% — 23 positive months versus 16 negative months.
Elevance Health ended November 2026 at $429.90, posting a monthly return of +2.34%. The S&P 500 returned +0.19% over the same window, leaving relative performance at +2.15%.
The current quarter stands at +10.57% (Q4 2026 (QTD)), while medium-term trend remains constructive: price is +14.83% versus the 200-day moving average ($374.39).
Year-to-date, ELV is +22.64% against SPY +11.03%, a gap of +11.61%. The stock is currently −4.61% below its 52-week high, with maximum 3-year drawdown at −51.15%.
| Period | ELV | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.10% | −0.35% | +0.45% |
| 1 Week | −0.49% | +3.29% | −3.78% |
| 1 Month | +2.34% | +0.19% | +2.15% |
| 3 Months | +7.39% | −2.48% | +9.86% |
| 6 Months | +9.31% | +2.00% | +7.31% |
| YTD | +22.64% | +11.03% | +11.61% |
| 12 Months | +31.22% | +10.79% | +20.42% |
| 3 Years | −6.19% | +71.83% | −78.02% |
| Rank | Month | Return |
|---|---|---|
| #1 | Apr 2026 | +28.58% |
| #2 | Aug 2025 | +12.57% |
| #3 | Mar 2025 | +9.59% |
| #4 | Oct 2026 | +8.04% |
| #5 | Jan 2025 | +7.26% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jul 2025 | −27.22% |
| #2 | Oct 2024 | −21.97% |
| #3 | Dec 2024 | −9.35% |
| #4 | May 2025 | −8.74% |
| #5 | Mar 2026 | −8.52% |
| Quarter | Return |
|---|---|
| Q3 2025 | −16.93% |
| Q4 2025 | +8.49% |
| Q1 2026 | −16.49% |
| Q2 2026 | +32.10% |
| Q3 2026 | +0.54% |
| Q4 2026 (QTD) | +10.57% |
| Year | Return |
|---|---|
| 2023 | −8.07% |
| 2024 | −21.77% |
| 2025 | −4.97% |
| 2026 | +22.64% |
| Metric | Value |
|---|---|
| 52-Week High | $450.69 (2026-10-21) |
| 52-Week Low | $274.84 (2026-03-09) |
| Current Price | $429.90 |
| 200-Day Moving Average | $374.39 |
| Price vs 200DMA | +14.83% |
| 3-Year Maximum Drawdown | −51.15% (2025-08-01) |
| Current Drawdown from 52W High | −4.61% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 54.2 |
| 3-Year Excess Return vs S&P 500 | −78.02% |
| RS Peak | 102.4 (Apr 2024) |
| RS Trough | 39.5 (Mar 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was ELV's return for this report period?
ELV returned +2.34% in the latest monthly window ending 2026-11-12.
Has ELV outperformed SPY year to date?
YTD ELV: +22.64% vs SPY: +11.03%.
What is ELV's 12-month return?
+31.22% over the trailing 12 months.
Is ELV above or below its 200-day moving average?
Price is +14.83% versus 200DMA ($374.39).
What is the maximum drawdown in the 3-year window?
−51.15% on 2025-08-01.